+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route of Administration, Dosage Form, Distribution Channel, Product Type - Global Forecast to 2030- Product Image
Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route of Administration, Dosage Form, Distribution Channel, Product Type - Global Forecast to 2030- Product Image
Sale

Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route of Administration, Dosage Form, Distribution Channel, Product Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015346
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Emphysema Treatment Market grew from USD 6.83 billion in 2024 to USD 7.32 billion in 2025. It is expected to continue growing at a CAGR of 7.04%, reaching USD 10.28 billion by 2030.

Pioneering Progress in Emphysema Management

Emphysema remains a formidable challenge within chronic obstructive pulmonary disease, demanding innovative therapeutic approaches and integrated care models. Over recent years, scientific breakthroughs in pharmacology and surgical interventions have converged to redefine standards of care. Emerging inhalation technologies and targeted biologics are complementing established bronchodilators, while minimally invasive procedures offer new hope for advanced cases.

This summary distills the critical developments impacting stakeholders across the value chain. It highlights paradigm shifts in treatment modalities, examines policy and tariff influences on global supply chains, and presents nuanced segmentation insights that uncover growth pockets and unmet needs. By weaving together industry trends, competitive dynamics, and regional nuances, this report equips decision-makers with the comprehensive perspective necessary to navigate an increasingly complex market environment.

Revolutionary Shifts Defining the Emphysema Treatment Ecosystem

A rapid transition is underway as the emphysema treatment ecosystem embraces personalized medicine, digital health convergence, and device innovation. Precision dosing algorithms powered by real-world data analytics are optimizing pharmacological regimens, while sensor-enabled inhalers ensure adherence and facilitate remote monitoring. Concurrently, the advent of bronchoscopic valve therapy and refined lung volume reduction techniques have expanded minimally invasive alternatives beyond conventional surgical approaches.

Collaborations between biotech firms and technology companies are accelerating the development of novel biologics that target protease-antiprotease imbalances, with several candidates entering late-stage clinical evaluation. The integration of artificial intelligence into diagnostic imaging platforms is enhancing early detection and phenotyping, enabling clinicians to tailor intervention strategies with unprecedented accuracy. These transformative shifts are collectively advancing patient outcomes and reshaping competitive landscapes by fostering value-based care models that align reimbursement with clinical efficacy.

Assessing the Ripple Effect of US Tariff Measures on Treatment Accessibility

In 2025, the cumulative impact of United States tariff measures has reverberated across pharmaceutical supply chains and device imports, creating headwinds in cost structures and procurement strategies. Increased duties on active pharmaceutical ingredients sourced from international partners have led manufacturers to reassess their supplier networks, with several electing to localize production or pursue alternative sourcing agreements to mitigate margin erosion.

Device innovators have similarly faced elevated costs for specialized inhaler components and surgical instruments, prompting OEMs to renegotiate distributor contracts or absorb incremental expenses to preserve competitive pricing. Payers and healthcare providers are responding by intensifying value assessments, emphasizing pharmacoeconomic data to justify reimbursements. As a result, companies are accelerating negotiations on integrated service offerings and outcome-based contracts, seeking to offset tariff-driven cost pressures through demonstrable improvements in patient adherence and reduced hospital readmissions.

Deep-Dive Segmentation Unveils Diverse Therapeutic Pathways

An in-depth segmentation reveals that treatment type remains the cornerstone of analysis, with pharmacological therapies encompassing antibiotics, bronchodilators, corticosteroids and mucolytics each addressing inflammatory and airflow obstruction pathways. Surgical avenues such as bullectomy, lung transplantation, lung volume reduction surgery and valve therapy continue to evolve with minimally invasive techniques, catering to patients with advanced emphysema unresponsive to medication.

Exploring drug class distinctions, anticholinergics, beta-agonists and combination drugs exhibit differing safety profiles, onset times and patient adherence characteristics, influencing formulary placement and clinician prescribing behavior. The therapy line segmentation differentiates adjunctive, first-line, maintenance and rescue interventions. Within maintenance care, combination therapy, long-acting anticholinergics and long-acting beta-agonists serve to sustain lung function over extended periods, while rescue options including short-acting anticholinergics and short-acting beta-agonists target acute symptom relief.

Route of administration analysis underscores the predominance of inhalation technologies-namely dry powder inhaler, metered dose inhaler, nebulizer and soft mist inhaler-offering direct pulmonary delivery, complemented by intravenous infusion and injection for systemic therapies and by traditional oral formats such as capsules, solutions and tablets. Dosage form segmentation reflects patient preference and device compatibility across capsules, inhalers, nebulizers, solutions and tablets. Distribution channels span hospital pharmacy, online pharmacy and retail pharmacy networks, each presenting unique access constraints and margin structures. Finally, the product type lens distinguishes brand innovations from generic equivalents, illuminating competitive dynamics driven by patent expiry, pricing pressures and biosimilar entry.

Regional Nuances Driving Emphysema Treatment Dynamics Globally

Regional dynamics underscore the Americas as a mature market with established reimbursement frameworks and robust patient support programs. North American healthcare systems are investing in digital adherence solutions and integrating telehealth consultations to reduce hospitalization rates. Latin American countries are gradually enhancing access to advanced inhalation devices, driven by public-private partnerships that subsidize essential respiratory therapies and bolster diagnostic capabilities in underserved areas.

In Europe, Middle East & Africa, heterogeneous regulatory landscapes and varied healthcare funding models create disparate adoption rates for novel treatments. Western Europe continues to lead in approving next-generation biologics and bronchoscopic interventions, while emerging markets in the Middle East and Africa prioritize cost-effective generics and basic bronchodilator therapies to address a growing disease burden.

Asia-Pacific presents a dynamic growth frontier characterized by rapid urbanization, escalating environmental risk factors and expanding healthcare infrastructure. Governments and payers in this region are fostering domestic pharmaceutical manufacturing and investing in community health initiatives to improve early detection. Regional centers of excellence are emerging for minimally invasive surgical training, positioning Asia-Pacific as both a significant demand hub and an innovation incubator.

Leading Innovators Propelling Therapeutic Excellence

Leading companies are differentiating through integrated platforms that combine advanced inhalation devices with companion digital tools. A major biopharmaceutical player has recently launched a triple-therapy inhaler featuring adaptive flow resistance to optimize drug deposition, while another has secured regulatory approvals for an antibody-based treatment aimed at neutralizing protease-mediated inflammation.

A specialist device manufacturer has gained traction with a next-generation soft mist inhaler designed to deliver consistent aerosol output regardless of inspiratory effort, and concurrently, a surgical innovation firm has expanded its portfolio of endobronchial valves offering customizable airflow modulation. Several generic drug producers have also intensified their focus on bioequivalent versions of established bronchodilators, driving price competition and increasing access in cost-sensitive markets.

Collaborative ventures between global pharmas and regional biotech startups are facilitating accelerated clinical trials of cell-based repair therapies, reflecting a broader shift toward regenerative approaches. These strategic alliances leverage combined expertise and shared resources to de-risk development and streamline approval pathways across multiple jurisdictions.

Strategic Roadmap for Advancing Emphysema Care

Industry leaders should prioritize end-to-end partnerships that link drug development with patient engagement platforms, ensuring seamless integration of digital adherence tracking into clinical workflows. Establishing strategic alliances with contract development and manufacturing organizations can safeguard supply chain resilience against tariff disruptions and raw material shortages.

Investment in real-world evidence generation will be critical to substantiate value-based contracting proposals, demonstrating tangible outcomes such as reduced exacerbations, hospital admissions and long-term healthcare utilization. Expanding clinical trial footprints to encompass diverse patient populations across emerging regions will enhance data representativeness and support broader regulatory acceptance.

Emphasizing flexible pricing models-such as subscription-style services or outcomes-based rebates-can align stakeholder incentives and mitigate payer scrutiny. Companies that proactively engage with professional societies and patient advocacy groups to co-create education programs will foster stronger brand loyalty and drive guideline adoption of new therapeutic modalities.

Rigorous Research Methodology Underpinning Market Insights

This analysis synthesizes insights gleaned from extensive primary and secondary research. In-depth interviews with pulmonologists, thoracic surgeons, payers and procurement specialists provided firsthand perspectives on clinical efficacy, adoption barriers and reimbursement trends. Proprietary surveys captured quantitative data on device utilization, patient adherence metrics and formulary placements across key markets.

Secondary sources including peer-reviewed journals, regulatory filings and government databases were rigorously reviewed to corroborate interview findings and ensure alignment with the latest clinical guidelines. Data triangulation techniques were applied to reconcile discrepancies and enhance overall reliability. A multi-stage validation process engaged an advisory board of experts to challenge assumptions and refine analytical models.

The result is a robust, multi-dimensional framework that illuminates competitive landscapes, regulatory influences and evolving patient needs without reliance on speculative projections. Comprehensive scenario analysis underpins each insight to guide strategic decision-making with confidence.

Convergence of Innovation and Strategy in Emphysema Care

The emphysema treatment landscape is at an inflection point, characterized by the fusion of innovative therapeutics, device advancements and digital health integration. Stakeholders who master the interplay between these domains will be best positioned to capture emerging opportunities and drive sustainable growth. Regulatory and tariff environments will continue to shape access and affordability, underscoring the need for adaptable supply chain strategies and outcome-based value propositions.

Consolidation pressures among device manufacturers and pharmaceutical companies are likely to intensify, favoring organizations with integrated capabilities spanning care delivery, data analytics and patient support. As regional markets evolve, local partnerships and customized approaches will be critical to addressing diverse patient needs and reimbursement structures. Ultimately, the convergence of clinical innovation and strategic agility will define success in the global emphysema market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Pharmacological
      • Antibiotics
      • Bronchodilators
      • Corticosteroids
      • Mucolytics
    • Surgical
      • Bullectomy
      • Lung Transplantation
      • Lung Volume Reduction Surgery
      • Valve Therapy
  • Drug Class
    • Anticholinergics
    • Beta-Agonists
    • Combination Drugs
  • Therapy Line
    • Adjunctive
    • First-Line
    • Maintenance
      • Combination Therapy
      • Long-Acting Anticholinergics
      • Long-Acting Beta-Agonists
    • Rescue
      • Short-Acting Anticholinergics
      • Short-Acting Beta-Agonists
  • Route Of Administration
    • Inhalation
      • Dry Powder Inhaler
      • Metered Dose Inhaler
      • Nebulizer
      • Soft Mist Inhaler
    • Intravenous
      • Infusion
      • Injection
    • Oral
      • Capsule
      • Solution
      • Tablet
  • Dosage Form
    • Capsule
    • Inhaler
    • Nebulizer
    • Solution
    • Tablet
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Product Type
    • Brand
    • Generic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • Chiesi Farmaceutici S.p.A.
  • Sunovion Pharmaceuticals Inc.
  • Sandoz International GmbH
  • Cipla Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Emphysema Treatment Market, by Treatment Type
8.1. Introduction
8.2. Pharmacological
8.2.1. Antibiotics
8.2.2. Bronchodilators
8.2.3. Corticosteroids
8.2.4. Mucolytics
8.3. Surgical
8.3.1. Bullectomy
8.3.2. Lung Transplantation
8.3.3. Lung Volume Reduction Surgery
8.3.4. Valve Therapy
9. Emphysema Treatment Market, by Drug Class
9.1. Introduction
9.2. Anticholinergics
9.3. Beta-Agonists
9.4. Combination Drugs
10. Emphysema Treatment Market, by Therapy Line
10.1. Introduction
10.2. Adjunctive
10.3. First-Line
10.4. Maintenance
10.4.1. Combination Therapy
10.4.2. Long-Acting Anticholinergics
10.4.3. Long-Acting Beta-Agonists
10.5. Rescue
10.5.1. Short-Acting Anticholinergics
10.5.2. Short-Acting Beta-Agonists
11. Emphysema Treatment Market, by Route of Administration
11.1. Introduction
11.2. Inhalation
11.2.1. Dry Powder Inhaler
11.2.2. Metered Dose Inhaler
11.2.3. Nebulizer
11.2.4. Soft Mist Inhaler
11.3. Intravenous
11.3.1. Infusion
11.3.2. Injection
11.4. Oral
11.4.1. Capsule
11.4.2. Solution
11.4.3. Tablet
12. Emphysema Treatment Market, by Dosage Form
12.1. Introduction
12.2. Capsule
12.3. Inhaler
12.4. Nebulizer
12.5. Solution
12.6. Tablet
13. Emphysema Treatment Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Emphysema Treatment Market, by Product Type
14.1. Introduction
14.2. Brand
14.3. Generic
15. Americas Emphysema Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Emphysema Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Emphysema Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. GlaxoSmithKline plc
18.3.2. Boehringer Ingelheim International GmbH
18.3.3. AstraZeneca plc
18.3.4. Novartis AG
18.3.5. Teva Pharmaceutical Industries Ltd
18.3.6. Viatris Inc.
18.3.7. Chiesi Farmaceutici S.p.A.
18.3.8. Sunovion Pharmaceuticals Inc.
18.3.9. Sandoz International GmbH
18.3.10. Cipla Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. EMPHYSEMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. EMPHYSEMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. EMPHYSEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EMPHYSEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. EMPHYSEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. EMPHYSEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 94. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 96. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 97. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 99. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 100. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 101. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 104. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 106. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 110. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 111. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 181. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 191. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 195. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 196. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 202. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 204. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 223. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 224. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 226. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 227. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 228. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 230. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 231. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 237. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 238. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 241. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 245. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 247. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SPAIN EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 292. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 293. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 294. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 296. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 297. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 298. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 300. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 302. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 314. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 315. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 316. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 317. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 320. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 321. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 322. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 324. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 325. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 326. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 327. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 328. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 329. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 330. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 331. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. QATAR EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 334. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 335. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2030 (USD MILLION)
TABLE 336. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 337. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 338. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2030 (USD MILLION)
TABLE 339. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2030 (USD MILLION)
TABLE 340. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 341. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 342. FINLAND EMPHYSEMA TREATMENT MARKET S

Companies Mentioned

The companies profiled in this Emphysema Treatment market report include:
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • Chiesi Farmaceutici S.p.A.
  • Sunovion Pharmaceuticals Inc.
  • Sandoz International GmbH
  • Cipla Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.32 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.28 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Emphysema Treatment Market Report and Forecast 2024-2032 - Product Image

Emphysema Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Emphysema Treatment Market Report 2025 - Product Image

Emphysema Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Emphysema Treatment Medication Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Emphysema Treatment Medication Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Emphysema Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Emphysema Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From

About the Market

The Emphysema Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat emphysema, a chronic lung disease that causes shortness of breath, coughing, and wheezing. These drugs are typically inhaled corticosteroids, bronchodilators, and phosphodiesterase-4 inhibitors. They are used to reduce inflammation, open airways, and improve breathing. The Emphysema Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Boehringer Ingelheim. Other companies, such as Sunovion, Teva Pharmaceuticals, and Mylan, also offer products in this market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.